Light-chain amyloid myopathy isolated to skeletal muscles: A case report
- PMID: 33363840
- PMCID: PMC7752340
- DOI: 10.1002/ccr3.3310
Light-chain amyloid myopathy isolated to skeletal muscles: A case report
Abstract
Isolated amyloidosis, especially of amyloid light-chain type, is an infrequent disease. Systemic chemotherapy for light-chain amyloidosis isolated to skeletal muscles plays a key role to reduce clonal plasma cells producing aberrant immunoglobulin.
Keywords: amyloidosis; isolated amyloid myopathy; light‐chain.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
None declared.
Figures
References
-
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538‐e548. - PubMed
-
- Prayson RA. Amyloid myopathy: clinicopathologic study of 16 cases. Hum Pathol. 1998;29(5):463‐468. - PubMed
-
- Perfetti V, Palladini G, Casarini S, et al. The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1‐44. Blood. 2012;119(1):144‐150. - PubMed
-
- Kourelis TV, Dasari S, Theis JD, et al. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light‐chain amyloidosis by mass spectrometry. Blood. 2017;129(3):299‐306. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
